PNDHF: Insider Participation in Private Placement Underscores Management's Confidence in Company Prospects By M. Marin OTCQB:PNDHF | TSX.V:POND READ THE FULL PNDHF RESEARCH REPORT Benzinga · Sep 15, 2022
FRXIF: A Stock On the Cusp of Catching On Fire By Brad Sorensen, CFA OTC:FRXIF READ THE FULL FRXIF RESEARCH REPORT Benzinga · Sep 14, 2022
CLMEF: An Energy Company with an Enticing Yield By Brad Sorensen, CFA OTC:CLMEF Benzinga · Sep 14, 2022
VSQTF: Q2 Report at Victory Square Shows Rapid Growth at IV Hydreight and XR Immersive By Lisa Thompson OTC:VSQTF READ THE FULL VSQTF RESEARCH REPORT Benzinga · Sep 14, 2022
GBLI: INITIATION: Smallcap specialty property & casualty insurer entering a new and focused growth phase. The company operates in specialty areas primarily in excess and surplus lines. By Thomas Kerr, CFA NYSE:GBLI READ THE FULL GBLI RESEARCH REPORT Benzinga · Sep 13, 2022
MCVT: An Old-Fashioned Money Maker in Volatile Times By Brad Sorensen, CFA NASDAQ:MCVT Benzinga · Sep 13, 2022
ALLR: A Precision Undertaking By John Vandermosten, CFA NASDAQ:ALLR READ THE FULL ALLR RESEARCH REPORT Benzinga · Sep 13, 2022
ATE.TO: Plans on Track for Acute Pain Program for Otenaproxesul… By David Bautz, PhD OTC:ATBPF | TSX:ATE.TO READ THE FULL ATE.TO RESEARCH REPORT Benzinga · Sep 12, 2022
ACOGF: Bioequivalence Complete By John Vandermosten, CFA OTC:ACOGF READ THE FULL ACOGF RESEARCH REPORT Benzinga · Sep 7, 2022
XTMIF: XTM Increases Revenues 224% in Q2 with a Fully Opened Hospitality Industry in Canada By Lisa Thompson OTC:XTMIF READ THE FULL XTMIF RESEARCH REPORT Benzinga · Sep 6, 2022
ALQGC: FRESH Results in November By John Vandermosten, CFA EPA:ALQGC READ THE FULL ALQGC RESEARCH REPORT Benzinga · Sep 6, 2022
RFHRF: Renforth Resources Continued to Advance Surimeau with a Spring Prospecting Campaign & a Summer Follow-Up Program Leading to Lalonde's Mineralized Strike Expanding from 2.5km to 9km. By Steven Ralston, CFA OTC:RFHRF READ THE FULL RFHRF RESEARCH REPORT Benzinga · Aug 31, 2022
VIVXF: OxC-beta Approved in China… By David Bautz, PhD MKT:TICKER READ THE FULL VIVXF RESEARCH REPORT Benzinga · Aug 31, 2022
SYTA: UPDATE: Siyata reports 2022 2nd quarter financial results and updates investor community on new distribution and partnership efforts. By Thomas Kerr, CFA NASDAQ:SYTA READ THE FULL SYTA RESEARCH REPORT Benzinga · Aug 31, 2022
Benzinga · Aug 30, 2022 STKH: UPDATE: The company reported 2nd quarter 2022 results which were largely inline with our estimates. The company also made a significant name change and rebranding during the quarter. By Thomas Kerr, CFA NASDAQ:STKH READ THE FULL STKH RESEARCH REPORT
Benzinga · Aug 30, 2022 ORMP: Upcoming data from ORA-D-013-1 & NASH studies could be catalysts By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT
Benzinga · Aug 24, 2022 VQS: Outlook Strong as Active Client Base Reaches Record Levels, Operations Resume in Key Verticals By M. Marin NASDAQ:VQS | TSX:VQS READ THE FULL VQS RESEARCH REPORT
Benzinga · Aug 24, 2022 NEXCF: Nextech Continues its Transition to AR and Metaverse Pure Play in Q2 By Lisa Thompson OTC:NEXCF READ THE FULL NEXCF RESEARCH REPORT
Benzinga · Aug 24, 2022 COCP: UPDATE: Cocrystal Pharma releases 2022 2nd quarter results and provides an update on the current pipeline programs. By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT
Benzinga · Aug 22, 2022 NHWK: Scorpion Grand Opening 3Q:22 By John Vandermosten, CFA NYSE:NHWK READ THE FULL NHWK RESEARCH REPORT
Benzinga · Aug 22, 2022 GTRIF: GTI Energy Ltd Focused on Acquiring and Advancing U.S.-based Uranium ISR Projects By Steven Ralston, CFA OTC:GTRIF | ASX:GTR READ THE FULL GTRIF RESEARCH REPORT
Benzinga · Aug 19, 2022 MNOV: Phase 2 Trial of MN-001 in NAFLD Patients with Type 2 Diabetes and Hypertriglyceridemia Underway… By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT
Benzinga · Aug 17, 2022 NOVN: EPI Revenue Trends Are Strong By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT
Benzinga · Aug 17, 2022 BTAI: SERENITY III Trial to Initiate in 2H22… By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT
Benzinga · Aug 16, 2022 DYAI: Dapibus on the Menu By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT